QIANJIANG YONGAN PHARMACEUTICAL CO., LTD.

Qianjiang Yongan Pharmaceutical Co., Ltd.

002365

CNE100000LZ9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-06-05 pm EDT			5-day change	1st Jan Change
7.06 ^CNY	-3.16%		-9.14%	-27.81%

Apr. 29	Qianjiang Yongan Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 80 million worth of its shares.	CI
Apr. 29	Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Qianjiang Yongan Pharmaceutical Co., Ltd. authorizes a Buyback Plan.

April 28, 2024

The Board of Directors of Qianjiang Yongan Pharmaceutical Co., Ltd. has authorized a buyback plan on April 29, 2024.

Latest news about Qianjiang Yongan Pharmaceutical Co., Ltd.

Qianjiang Yongan Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 80 million worth of its shares.	Apr. 29	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	Apr. 28	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 18	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-23	CI
Qianjiang Yongan Pharma Patents Purification Method For Taurine Mother Liquor in Europe, Indonesia	23-08-09	MT
Qianjiang Yongan Pharmaceutical Co., Ltd Approves Cash Dividend for the Year 2022, Payable on July 5, 2023	23-06-21	CI
Yongan Pharma Registers New Health Food Products	23-06-06	MT
Qianjiang Yongan Pharma to Buy 6.5% Stake in Local Chemical Producer For 30 Million Yuan	23-05-24	MT
Huanggang Yongan Pharmaceutical Co., Ltd. announced that it expects to receive CNY 30 million in funding from Qianjiang Yongan Pharmaceutical Co., Ltd.	23-05-22	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-27	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year 2022	23-03-30	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Yongan Pharma Unit Gets Food Registration Certificate for Ginseng Tablets	23-01-06	MT
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-25	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-25	CI
Qianjiang Yongan Pharma Patents Taurine, Salt Preparation in Japan	22-08-11	MT
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-24	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-26	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-27	CI
Qianjiang Yongan Pharmaceutical Co., Ltd. Announces Final Cash Dividend for 2020, Payable on July 9, 2021	21-07-05	CI
Yongan Pharmaceutical Approves Final Cash Dividend for the Year 2020	21-06-29	CI
Wuhan Low-dimensional Materials Research Institute Co., Ltd. announced that it has received CNY 10 million in funding from Qianjiang Yongan Pharmaceutical Co., Ltd.	21-06-09	CI

Chart Qianjiang Yongan Pharmaceutical Co., Ltd.

Duration

Period

Chart Qianjiang Yongan Pharmaceutical Co., Ltd.

More charts

Qianjiang Yongan Pharmaceutical Co., Ltd. is a China-based company principally engaged in the manufacture and sales of taurine products. The Company operates through three main segments. The Taurine Products segment is mainly engaged in the research, development, manufacture and sales of taurine products, as well as the manufacture and sales of ethylene oxide. The Food Supplement segment is mainly involved in the research, development, manufacture and sales of dietary supplement, as well as the import and sales of overseas dietary supplement. The Health Field segment is mainly involved in the equity or industrial investment in health-related field.

Sector

Pharmaceuticals

Calendar

2024-06-21 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
QIANJIANG YONGAN PHARMACEUTICAL CO., LTD.	-27.81%	287M
ELI LILLY AND COMPANY	+46.38%	754B
NOVO NORDISK A/S	+41.70%	630B
JOHNSON & JOHNSON	-6.41%	352B
MERCK & CO., INC.	+20.12%	331B
ABBVIE INC.	+8.94%	298B
ASTRAZENECA PLC	+18.70%	250B
NOVARTIS AG	+11.96%	217B
ROCHE HOLDING AG	-0.78%	216B
AMGEN INC.	+6.06%	164B

Other Pharmaceuticals